The Aenova Group (Pahl, Germany) is to acquire Temmler Group (Marburg, Germany) for an undisclosed price. Aenova, which generates annual revenues of around €280 million, is a European provider of development, manufacturing, and marketing services for medicines and dietary supplements. Its portfolio consists of solid dosage forms, such as soft gelatin capsules, hard capsules, conventional tablets, film-coated tablets, and effervescent tablets. Temmler Group is an international pharmaceutical company and full service provider for pharmaceutical contract manufacturing. It has seven production sites in Europe and revenues of around €170 million. Equity for the transaction is being provided by funds advised by BC Partners, which acquired Aenova in August 2012.
Disclaimer: NCN does not warrant the accuracy, reliability, or timeliness of any NCN news item. Before relying on any NCN News item the information should be independently verified.
For more finance and investment information, visit Nutrition Capital Network news